Raseglurant - Addex Therapeutics
Alternative Names: ADX-10059Latest Information Update: 19 Aug 2019
Price :
$50 *
At a glance
- Originator Addex Pharmaceuticals
- Class Amines; Anxiolytics; Pyridines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 5 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Drug-induced dyskinesia; Gastro-oesophageal reflux; Migraine; Parkinson's disease
Most Recent Events
- 19 Aug 2019 Chemical structure information added
- 15 Dec 2009 Discontinued - Phase-II for Gastro-oesophageal reflux in European Union (PO)
- 15 Dec 2009 Discontinued - Phase-II for Gastro-oesophageal reflux in USA (PO)